Observations, lessons, and takeaways from Monday’s failure of Gilead Sciences’ (GILD) NASH drug, selonsertib.
1. In defense of Gilead, a broad swath of Wall Street’s covering analysts argued the negative outcome of the Phase 3 study was expected and therefore already baked into the biotech’s diminished stock price.
Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!
GET STARTEDWhat is it?
STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What's included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- Online intelligence briefings
- Frequent opportunities to engage with veteran beat reporters and industry experts
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
About the Author
cnat future results?
Seems CBAY has been forgotten about in the NASH market, maybe it is a prove it story, but seems worth keeping an eye on since other assets are struggling